Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Aripiprazolo

Abilify, Abilify Maintena e altri

Bibliografia - Quali fonti bibliografiche per Aripiprazolo?

  1. Agenzia Italiana del farmaco – AIFA, Abilify Maintena . Riassunto caratteristiche di Prodotto, 2022, https://farmaci.agenziafarmaco.gov.it/ (accesso: giugno 2023)

  2. Agenzia Italiana del Farmaco – AIFA, Abilify – Riassunto caratteristiche di Prodotto, 2023 https://farmaci.agenziafarmaco.gov.it/ (accesso: maggio 2023).

  3. Alsayouf H.A. et al., Children (Basel), 2021, 8 (5), 318.

  4. Andrade C., J. Clin. Psychiatry, 2022, 83 (3), 22f14529.

  5. Aung G.L. et al., Ann Pharmacother., 2010, 44 (11), 1850.

  6. Austr. Adv. Drug. Reactions Bull., 2007, 26 (2), 2.

  7. Azuma J. et al., Eur. J. Clin. Pharmacol., 2012, 68 (1), 29.

  8. Beach S.R. et al., Psychosomatics., 2018, 59 (2), 105.

  9. Bellantuono C. et al., Riv. Psichiatr., 2015, 50 (1), 8.

  10. Bordet C. et al., Psychopharmacology (Berl), 2023, 240 (1), 199.

  11. Boulton D.W et al., J. Clin. Pharm. Ther., 2012, 37 (5), 565.

  12. Caykoylu A. et al., J. Clin. Psychopharmacol., 2011, 31 (1), 134.

  13. Chen W.H. et al., J. Clin. Neurosci., 2005, 12 (2), 161.

  14. Cheng Z. et al., J. Psychopharmacol., 2019, 33 (10), 1227.

  15. Chrzanowski W.K. et al., Psychopharmacology (Berl), 2006, 189 (2), 259.

  16. Church C.O., et al., Diabet. Med., 2005, 22, 1440.

  17. Citrome L. et al., J. Clin. Pharmacol., 2005, 45 (1), 89.

  18. Correll C.U. et al., JAMA, 2009, 302 (16), 1765.

  19. Cox J.H. et al., Pediatric Health Med. Ther., 2016, 7, 57.

  20. Cuomo A. et al., J. Affect. Disord., 2018, 228, 229.

  21. D’Urso G. et al., Exp. Clin. Psychopharmacol., 2018, 26 (5), 509.

  22. Fernández-Abascal B. et al., Ther. Adv. Psychopharmacol., 2021, 11, 1.

  23. Findling R.L. et al., Am. J. Psychiatry, 2008, 165 (11), 1432.

  24. Findling R.L. et al., J. Child Adolesc. Psychopharmacol., 2008a, 18 (4), 347.

  25. Findling R.L. et al., J. Clin. Psychopharmacol., 2008b, 28 (4), 441.

  26. Findling R.L. et al., J. Clin. Psychiatry, 2009, 70 (10), 1441.

  27. Findling R.L. et al., Bipola Didord., 2013, 15 (2), 138.

  28. Findling R.L. et al., J. Clin. Psychiatry, 2014; 75 (1), 22.

  29. Food and Drug Administration – FDA, Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada), 2016, 3 maggio https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-new-impulse-control-problems-associated-mental-health

  30. Food and Drug Administration – FDA, Abilify – Prescribing Information. 2022 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021436s048lbledit.pdf (accesso: marzo 2023).

  31. Food and Drug Administration – FDA, Abilify AsimtufII – Prescribing Information, 2023 (accesso: aprile 2024).

  32. Fountoulakis K.N. et al., Ann. Pharmacother., 2006, 40,775.

  33. Fraguas D. et al., Eur. Neuropsychopharmacol., 2011, 21 (8), 621.

  34. Ghanizadeh A., Haghighi A., Child. Psychiatry Hum. Dev., 2014, 45 (5), 596.

  35. Gennaro-Mattos T.C. et al., Mol. Psychiatry, 2019, 24 (4), 491.

  36. Germanò E. et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2014, 51, 23.

  37. Gill S.S. et al., Ann. Intern. Med., 2007, 146, 775.

  38. Hahn M., Roll S.C., Drug Saf. Case Rep., 2016, 3 (1), 5.

  39. Hart X.M. et al., Psychopharmacology (Berl.), 2022, 239 (11), 3377.

  40. Hendset M. et al., Ther. Drug Monit., 2010, 32 (6), 787.

  41. Ho J.G. et al., J. Child Adolesc. Psychophamacol., 2012, 22 (4), 277.

  42. Kane J.M. et al., J. Clin. Psychiatry, 2009, 70 (4), 572.

  43. Kasper S. et al., Int. J. Neuropsychopharmacol., 2003, 6 (4), 325.

  44. Keck P.E. Jr et al., Am. J. Psychiatry, 2003, 160 (9), 1651.

  45. Keck P.E. et al., J. Clin. Psychiatry, 2007, 68 (10), 1480.

  46. Keck P.E. Jr. et al., J. Clin. Psychiatry, 2006, 67 (4), 626.

  47. Kirino E., Clin. Schizophr. Relat. Psychoses., 2010, 4 (3), 185.

  48. Kirino E, Adolesc. Health Med. Ther., 2014, 5, 211.

  49. Kiss A. et al., Eur. Arch. Psychiatry Clin. Neurosci., 2020, 270 (1), 71.

  50. Komaroff A., Case rep. Womens Health., 2021, 30, e00308.

  51. Kozian R. et al., Psychiatr. Prax., 2019, 46 (1), 49.

  52. Korade Z. et al., J. Lipid Res., 2017, 58 (11), 2139.

  53. LactMed, Aripiprazole, 2022 https://www.ncbi.nlm.nih.gov/books/NBK501016/ (accesso: giugno 2023).

  54. Lindsey R. et al., J. Am. Acad. Child Adolesc.Psychiary, 2003, 42, 1268.

  55. Liu Y. et al., J. Child. Adolesc. Psychopharmacol., 2016, 26 (5), 436.

  56. Lutz U.C. et al., J. Clin. Psychopharmacol., 2010, 30 (2), 204.

  57. Mace S., Taylor D., CNS Drugs, 2009, 23 (9), 773.

  58. Mallikaarjun S. et al., J. Clin. Pharmacol., 2004, 44 (2), 179.

  59. Mankoski R. et al., J. Chil. Adolesc. Psychopharmacol., 2013, 23 (8), 572.

  60. Marcus R.N. et al., J. Am. Acad. Child Adolesc. Psychiatry, 2009, 48 (11), 1110.

  61. Marder S.R. et al., Schizophr. Res., 2003, 61 (2-3), 123.

  62. Margraff T. et al., Basic Clin. Pharmacol. Toxicol., 2023, 133 (1), 73.

  63. Matos A. et al., Pharmacy (basel), 2020, 8 (2), 63.

  64. Miniati M. et al., ScientificWorldJournal, 2017, 2017, 1951628.

  65. Morin C., Chevalier I., Breastfeed Med. 2017, 12 (6), 377.

  66. Newcomer J.W. et al., J. Clin. Psychiatry, 2008, 69 (7), 1046.

  67. Newton T.F. et al., Int. J. Neuropsychopharmacol., 2008, 11 (8), 1037.

  68. Nordeng H. et al., J. Clin. Psychopharmacol., 2014, 34 (2), 272.

  69. Nussbaum L. A. et al., Rom. J. Morphol. Embryol., 2014, 55 (3), 877.

  70. Oulis P. et al., J. Neuropsychiatry Clin. Neurosci, 2012 Summer, 24 (3), E39.

  71. Owen R. et al., Pediatrics., 2009, 124 (6), 1533.

  72. Pagsberg A.K. et al., Lancet Psychiatry, 2017, 4 (8), 605.

  73. Pancheri P., Tarsitani L., Journal of Psychopathology, 2005, Issue 1.

  74. Perez-lloret S. et al., J. Clin. Psychopharmacol., 2012, 32 (6), 824.

  75. Pigott T.A. et al., J. Clin. Psychiatry, 2003, 654 (9),1048.

  76. Potkin S.G. et al., Arch. Gen. Psychiatry, 2003, 60 (7),681.

  77. Pozzi M. et al., Eur. Child Adolesc. Psychiatry, 2022, 31 (1), 21.

  78. Rafaniello C. et al., Front. Psychiatry, 2020, 11, 550201.

  79. Regione Emilia Romagna – Commissione Regionale del Farmaco, Aripiprazolo, 2011.

  80. Ries R., Sayadipour A., J. Psychiatr. Pract., 2014, 20 (5), 338.

  81. Rolland B. et al., Clin. Neuropharmacol., 2013, 36 (3), 98.

  82. Sallee F. et al., J. Chil. Adolesc. Psychopharmacol., 2017, 27 (9), 771.

  83. Savitz A.J. et al., J. Am. Child Adolesc. Psychiatry, 2015, 54 (2), 126.

  84. Schonberger R.B. et al., Pediatrics, 2004, 114 (6), 1743.

  85. Schonfelt-Lecuona C., Connemann B.J., Am. J.Psychiatry, 2004, 161, 373.

  86. Snarr B.S. et al., Ann. Pharmacother., 2010, 44 (4), 760.

  87. Stefatos A. et al., Innov. Clin. Neurosci., 2018, 15 (5-6), 43.

  88. Strawn J.R. et al., J. Child Adolesc. Psychopharmacol., 2007, 17 (5), 733.

  89. Sugimoto Y. et al., BMC Psychiaty, 2021, 21 (1), 204.

  90. Szota A.M. et al., J. Psychoactive Drugs, 2022, 54 (3), 284.

  91. Tallman K.A. et al., ACS Chem. Neurosci., 2021, 12 (4), 735.

  92. Taylor D.M., Int. J. Clin. Pract., 2003, 57 (1), 49.

  93. Tosato S. et al., J. Clin. Psychiatry, 2017, 78 (5), e477.

  94. Touafchia D. et al., Hum. Psychopharmacol., 2020, 35 (4), e2734.

  95. Tramontina S. et al., J. Clin. Psychiatry, 2009, 70 (5), 756.

  96. Tseng P-T. et l., Int. J. Psychiatry Med., 2015, 49 (1), 35.

  97. Uttley L., et al., Pharmaeconomics., 2013, 31, (11), 981.

  98. Van Meter A.R. et al., J. Clin. Psychiatry, 2011, 72 (9), 1250.

  99. Vieta E. et al., Br. J. Psychiatry, 2005, 187, 235.

  100. Viguera A.C. et al., Arch. Womens Ment. Health., 2022, 25 (2), 511.

  101. Vijay Kumar K.G. et al., Indian J. Psychol. Med., 2021, 43 (5), 456.

  102. Waade R.B. et al., Ther. Drug Monit., 2009, 31 (2), 233.

  103. Westin A.A. et al., Clin. Pharmacol. Ther., 2018, 103 (3), 477.

  104. Winans E., Am. J. Health Syst. Pharm., 2003, 60 (23), 2437.

  105. Wu H. et al., Schizophr. Bull., 2022, 48 (3), 643.

  106. Yang C-S. et al., BMC Psychiatry, 2015, 15, 179.

  107. Yoo H.K. et al., J. Clin. Psychiatry, 2013, 74 (8), e772.

  108. Youmngstrom E. et al., J. Child Adolesc. Psychopharmacol., 2013, 23 (2), 72.